Mark M. Pomerantz

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer

Mark M. Pomerantz, Nasim Ahmadiyeh, Jia Li et al. · Nature Genetics · 2009 · 666 citations · Full text

Medicine, Genetics, Oncology +16

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis

Mark M. Pomerantz, Fugen Li, David Y. Takeda et al. · Nature Genetics · 2015 · 490 citations · Full text

Medicine, Oncology, Urology +13

8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with <i>MYC</i>

Nasim Ahmadiyeh, Mark M. Pomerantz, Chiara Grisanzio et al. · Proceedings of the National Academy of Sciences · 2010 · 366 citations

Medicine, Genetics, Molecular Genetics +17

A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer

David Y. Takeda, Sándor Spisák, Ji-Heui Seo et al. · Cell · 2018 · 337 citations · Full text

Medicine, Molecular Biology, Oncology +14